Excellent outcome of younger patients (18–60 years) with favorable-prognosis diffuse large B-cell lymphoma (DLBCL) treated with 4 cycles CHOP plus 6 applications of rituximab: results of the 592 patients of the FLYER trial of the DSHNHL/GLA - Poeschel, V; Held, G; Ziepert, M (Blood, 2018)
. doi:https://doi.org/10.1182/blood-2018-99-112403